Simultaneous Determination of the β-Blocker Atenolol and Several Complementary Antihypertensive Agents in Pharmaceutical Formulations and Urine by Capillary Zone Electrophoresis

Journal of Chromatographic Science

Volumn 36, Issue 10, 1998, Pages 516-522

  Maguregui, M I ^a   Jimenez R M ^a   Alonso, R M ^a  

^a UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT;

ARTICLE; CAPILLARY ELECTROPHORESIS; HUMAN; METHODOLOGY; PH; PHARMACEUTICS; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; STATISTICS; URINE;

ADRENERGIC BETA-ANTAGONISTS; ANTIHYPERTENSIVE AGENTS; ATENOLOL; ELECTROPHORESIS, CAPILLARY; HUMANS; HYDROGEN-ION CONCENTRATION; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TECHNOLOGY, PHARMACEUTICAL;

EID: 0032187250     PISSN: 00219665     EISSN: None     Source Type: Journal    
DOI: 10.1093/chromsci/36.10.516     Document Type: Article

References (33)

1. V. Caplar, Z. Mikotic-Mihun, H. Hoffman, J. Kuftinec, and F. Kajfez. Atenolol. Anal. Profiles of Drug Subst. 13: 1-25 (1984).
2. V. Marko. Determination of β-Blockers in Biological Material. Elsevier Science Publishers, Amsterdam, the Netherlands, 1989, pp 10-13.
3. A.N. Wadworth, D. Murdoch, and R.N. Brogden. Atenolol. A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disorders. Drugs 42(3): 468-510 (1991).
4. P. Weis, R.M. Hersey, C.A. Dujovne, and J.R. Bianchine. Clin. Pharmacol. Ther. 10: 401-406 (1969).
5. C. Verghese, A. McLeod, and D. Shand. Rapid high performance liquid chromatographic method for the measurement of atenolol in plasma using UV detection. J. Chromatogr. Biomed. Appl. 275: 367-75 (1983).
6. A. Tracqui, P. Kintz, J. Himber, A.A.J. Lugnier, and P. Mangin. A specific HPLC method for determination of beta-blockers topically used in opthamological diseases. Forensic Sci. Int. 38: 37-41 (1988).
7. M. Johansson and H. Forsmo-Bruce. Determination of atenolol in plasma by dual-column liquid chromatography and fluorimetric detection. J. Chromatogr. 432: 265-72 (1988).
8. M.T. Kelly, M.R. Smyth, and D. Dadgar. Retention characteristics in high-performance liquid chromatography of basic drugs and plasma extracts on an alumina column. J. Chromatogr. 473: 53-62 (1989).
9. M.T. Kelly and M.R. Smyth. A comparison of silica and alumina columns for high-performance liquid chromatographic separations of basic drugs and plasma constituents following on-line solid-phase extraction with column switching. J. Pharm. Biomed. Anal. 7(12): 1757-64 (1989).
10. M. Bogusz and M. Wu. Standardized HPLC/DAD system, based on retention indices and spectral library, applicable for systematic toxicological screening. J. Anal. Toxicol. 15: 188-97 (1991).
11. M.S. Leloux and F. Dost. Doping analysis of beta-blockng drugs using high-performance liquid chromatography. Chromatographia 32(9/10): 429-35 (1991).
12. W.E. Lambert, E. Meyer, and A.P. de Leenheer. Systematic toxicological analysis of basic drugs by gradient elution of an alumina-based HPLC packing material under alkaline conditions. J. Anal. Toxicol. 19(2): 73-78 (1995).
13. M.T. Saarinen, H. Sirén, and M.L. Riekkola. Screening and determination of β-blockers, narcotic analgesics and stimulants in urine by high-performance liquid chromatography with column switching. J. Chromatogr. Biomed. Appl. 664: 341-46 (1995).
14. K.U. Bühring and A. Garbe. Determination of the new β-blocker bisoprolol and of metoprolol, atenolol and propranolol in plasma and urine by high-performance liquid chromatography. J. Chromatogr. Biomed. Appl. 382: 215-24 (1986).
15. R. Mehvar. Liquid chromatographic analysis of atenolol enantiomers in human plasma and urine. J. Pharm. Sci. 78(12): 1034-39 (1989).
16. S.K. Chin, A.C. Hui, and K.M. Giacomini. High-performance liquid chromatographic determination of beta-adrenoreceptor blocking agents in biological fluids. II. Studies with atenolol. J. Chromatogr. Biomed. Appl. 489: 438-45 (1989).
17. T.A. Kolbah, F. Plavsíc, and A.W. Coporda. Determination of serum atenolol using HPLC with fluorescence detection following isolation with activated charcoal. J. Pharm. Biomed. Anal. 7(12): 1777-81 (1989).
18. A.D. Dale and S.E. Turner. The analysis of atenolol in plasma using an automated sample preparation technique. J. Pharm. Biomed. Anal. 8(8-12): 1055-58 (1990).
19. R.G. Morris, N.C. Saccoia, B.C. Sallustio, and R. Zacest. Improved high-performance, liquid chromatography assay for atenolol in plasma and urine using fluorescence detection. Ther. Drug Monit. 13: 345-49 (1991).
20. I. Carretero, M. Maldonado, and J.J. Laserna. Flourescencia inducida por laser para la detecion de drogas prohibidas en el mediante chromatografia liquida micelar. Química Analítica 11(2): 107-19 (1992).
21. P. Lukkari and H. Sirén. Ion-pair chromatography and micellar electrokinetic capillary chromatography in analyzing beta-adrenergic blocking agents from human biological fluids. J. Chromatogr. 717: 211-17 (1995).
22. F.T. Delbeke, M. Debackere, N. Desmet, and F. Maertens. Qualitative gas chromatographic and gas chromatographic-mass spectrometric screening for β-blockers in urine after solid-phase extraction using Extrelut-1 columns. J. Chromatogr. 426: 194-201 (1988).
23. H. Sirén, M. Sarinen, S. Hainari, P. Lukkari, and M.L. Riekkola. Screening of β-blockers in human serum by ion-pair chromatography and their identification as methyl or acetyl derivatives by gas chromatography-mass spectrometry. J. Chromatogr. 632: 215-27 (1993).
24. A. Solans, M. Carnicero, R. de la Torre, and J. Segura. Comprehensive screening procedure for detection of stimulants, narcotics, adrenergic drugs, and their metabolite in human urine. J. Anal. Toxicol. 19: 104-14 (1995).
25. S.I. SáSá, I.M. Jabal, and H.S. Khalil. Determination of atenolol combinations with hydrochlorothiazide and chlorthalidone in tablet formulations by reverse phase HPLC. J. Liq. Chromatogr. 11(8): 1673-96 (1988).
26. P. Lukkari, H. Sirén, M. Pantsar, and M.L. Riekkola. Determination of ten β-blockers in urine by micellar electrokinetic capillary chromatography. J. Chromatogr. 632: 143-48 (1993).
27. P. Lukkari, T. Nyman, and M.L. Riekkola. Determination of nine β-blockers in serum by micellar electrokinetic capillary chromatography. J. Chromatogr. 674: 241-46 (1994).
28. E. Gonzalez and J.J. Laserna. Capillary zone electrophoresis for the rapid screening of banned drugs in sports. Electrophoresis 15: 240-43 (1994).
29. J.M. Vadillo, M.E. Gonzalez, I. Carretero, and J.J. Laserna. Evaluation of micellar liquid chromatography and capillary zone electrophoresis for dope control in sport. Mikrochim. Acta 118: 273-82 (1995).
30. J.C. Hudson, M. Golin, and M. Malcolm. Capillary zone electrophoresis in a comprehensive screen for basic drugs in whole blood. Can. Soc. Forensic Sci. 28(2): 137-52 (1995).
31. M.I. Maguregui, R.M. Alonso, and R.M. Jiménez. Capillary zone electrophoretic method for the quantitative determination of the β-blocker atenolol in human urine. J. Liq. Chromatogr. In press.
32. B.R. Simmons and J.T. Stewart. HPLC determination of atenolol in human serum on underivatized silica using solid phase extraction. Anal. Lett. 28(11): 2017-26 (1995).
33. D.J. Chatterjee, W.Y. Li, A.K. Hurst, and R.T. Koda. High-performance liquid chromatographic method for determination of atenolol from human plasma and urine: simultaneous fluorescence and ultraviolet detection. J. Liq. Chromatogr. 18(4): 791-806 (1995).